Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. - Wikidata - wikimedia - TriplyDB

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.

http://www.wikidata.org/entity/Q34957243

about

Genomic landscape of human papillomavirus-associated cancers Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience.Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer.Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience Growth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway.Somatic Host Cell Alterations in HPV Carcinogenesis.The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy.Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.Determination of Puquitinib in Human Plasma by HPLC-ESI MS/MS: Application to Pharmacokinetic Study.Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer

P2860

Q26997399-A2665335-5097-4A5A-A760-705FB4B98F9A Q33779691-585B1524-AE4B-4520-A9BA-32F36BA697E8 Q35885555-11A58EF7-97D6-4BE3-A799-5F5C6129A402 Q36049360-EB847F0D-C770-48B6-9823-6768E0CB116C Q36206239-2222E5D7-3580-4974-9D63-694410C9A081 Q36685569-5E9032C6-2716-4924-8580-09A4D9B3040C Q36937086-480AA58A-58DC-42B5-BA6A-CBD4561C04B6 Q37082560-96B9EDDA-1957-4A9B-95E8-BC72A748A043 Q37376481-562CA98A-9458-43EA-A446-2FFDCC1DEF55 Q37401006-B16D6BBA-B5E2-4385-AAA4-4FE5641889D4 Q37577932-DF34DE50-2E41-484F-ADED-EEF663B35BEC Q37629030-F6AB56B1-298A-4E22-88F9-EA2B376C7C58 Q40096622-A1AA31F9-2F45-48FD-8140-87140D4800C4 Q48185689-B977AF75-ED6F-4665-A510-708E71AD2B6D Q49228103-EC57AAAA-9457-44C5-8327-AC5BFB2E75F5 Q52607328-B4D74AEA-6FED-445E-9594-F1801C916562 Q52665380-BC1F353A-4F17-44F1-A266-095ADAD5DA25 Q57117154-AC8257DC-F164-4483-9C13-8403DB030DA0

P2860

Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.

http://www.wikidata.org/entity/Q34957243

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@ast

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@en

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@nl

type

label

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@ast

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@en

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@nl

prefLabel

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@ast

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@en

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@nl

P1433

Q34957243-8849B587-10B7-4D1B-A262-C46E4C7A4BAC

P1476

Q34957243-A09CDF66-A7C0-4A00-B753-E64698F8A69D

P2093

Q34957243-039317A8-8335-4825-A830-19491AA5D30C

Q34957243-0EABDC65-6B16-4E36-9604-BC212E32B217

Q34957243-695AB8A6-9F10-44DE-820E-30EF2B6F1521

Q34957243-7AF45E01-B1FC-4B0B-802C-A98EC059CACD

Q34957243-9B4A2BB4-D95D-4169-B623-58BAB93E441E

Q34957243-C014F190-7DA1-48A5-811B-3E0A415A9116

Q34957243-CB0ECEFE-02AD-47D1-8FE0-81370DBFA875

Q34957243-FD77971C-063A-4639-8E5A-34F0F73957B2

P2860

Q34957243-02C389F7-685C-4A99-AA8B-FE97D9F44C1E

Q34957243-070D6026-20DE-4C53-8059-2163A4E3A72F

Q34957243-07FAF7F8-9AA8-4CAF-AEF4-BB54C3C6D40D

Q34957243-0C786DA1-E19A-4BFB-9C81-EEE725F25B89

Q34957243-16477F70-9443-4499-A2F5-B24096E13152

Q34957243-1965B4D6-44B5-4F4A-8E3A-03CECCC41044

Q34957243-197D8D74-A3FD-4750-B62E-6B1AB56E93CA

Q34957243-1B7BAAB1-F3A8-4A50-B554-0BCCB8DCE40B

Q34957243-283E493D-749E-49F8-B299-28D1487307D1

Q34957243-2DDEC134-F6C3-413B-A7C9-57C35BC10836

P304

Q34957243-2AB1F3FF-049F-4B80-B902-1102128245BF

P31

Q34957243-676272FB-80A8-47E8-B95A-1F283E14445B

P356

Q34957243-933D8873-535C-441C-92D1-0D8969C0B2D8

P407

Q34957243-01103FEE-795B-499E-BDB7-FB09168BFB13

P433

Q34957243-BC0CC6D6-E2B2-4A6B-99F7-D9F3C936F10E

P478

Q34957243-B4A760B9-8741-4EC7-AFBF-50464E4EA627

P50

Q34957243-0D259E7D-E359-4FBF-8157-A1DA2B5E43DA

Q34957243-112AFAC8-39C2-4455-ACF4-D6D3A1E86263

Q34957243-DBA37002-83F0-4C51-9B54-6B4CCF4D0C30

Q34957243-DE579F43-C873-4CB1-8F75-213A560A5D0E

P577

Q34957243-D64866D8-753D-4E50-B4EB-4EEACC83B6B0

P5875

Q34957243-956FA824-90A2-43E8-A4E6-0FA2A68B58C5

P698

Q34957243-B40F5B42-CEE9-455D-B5BD-4C6C01E988D6

P932

Q34957243-FB064079-544C-40FD-8B34-63134EA4A11B

P356

ONCOTARGET.2584

P1433

P1476

Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.

@en

P2093

David Hong

http://www.w3.org/2001/XMLSchema#string

Jennifer Wheler

http://www.w3.org/2001/XMLSchema#string

Karen Lu

http://www.w3.org/2001/XMLSchema#string

Ming-Mo Hou

http://www.w3.org/2001/XMLSchema#string

Ralph Zinner

http://www.w3.org/2001/XMLSchema#string

Robert L Coleman

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Xiaochun Liu

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Cancer statistics, 2014

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

PIK3CA as an oncogene in cervical cancer

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review.

Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.

Improved survival with bevacizumab in advanced cervical cancer

Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition

NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma

P304

11168-11179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2584

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Apostolia Maria Tsimberidou

P577

2014-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268874165

http://www.w3.org/2001/XMLSchema#string

P698

25426553

http://www.w3.org/2001/XMLSchema#string

P932

4294378

http://www.w3.org/2001/XMLSchema#string